Anna Newton advises life sciences clients on strategy development related to changes in the healthcare marketplace, including how policy and commercial developments impact their business.

She applies her background in policy and project management to support clients with research and analysis that span healthcare sectors and stakeholders. As a Lean Six Sigma Green Belt, she has experience in refining healthcare operations and quality management to improve outcomes.

Prior to joining Avalere, Anna was a project manager in Emory Healthcare’s Office of Quality, managing the development and implementation of new process flows and accompanying data analytics. She was also an associate at Woodcock & Associates, developing case studies of member organizations and designing and maintaining a bench-marking database in the realm of patient access to enhance member analysis and comparison.

Anna has an MPH in health policy and management and a BS in biology and public health from the College of William and Mary.

Authored Content

The Patient Centered Outcomes Research Institute (PCORI) recently announced an open comment period for a new set of proposed national priorities to inform its research agenda. Avalere analysis finds that from March 2019 to September 2020, PCORI directed roughly $259 million to comparative effectiveness research (CER) awards with an increasing share of new projects focused on drugs.

Avalere analysis found that in 2017 and 2018, more than half (56%) of Medicare patients with breast cancer taking a medicine covered by Medicare Part B received a therapy that was not routinely covered by England’s National Health Service (NHS) or its Cancer Drug Fund (CDF).

Avalere collaborates with the Endocrine Society and Pottstown Medical Specialists to launch a quality improvement intervention study aimed at addressing care gaps in the identification and management of hypoglycemia in older adults with type 2 diabetes.